VEON Ltd. (VEON)

Every figure this model derived for VEON, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

The ratios

The figures themselves rather than their scores — what somebody looking up VEON on one particular measure came for.

Everything else this filing tags

362 more elements from VEON's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.

What to be careful about

What this model itself distrusts about VEON's figures. Written by the derivation as it ran, not added afterwards.

• revenue is annual, not TTM
• operating income is annual, not TTM
• the market value here was 149.2B: 1.8B shares from the filing at the quoted price. The price feed reports 68.9M shares, and that count at this same price gives 5.6B, which is the value the feed itself reports. So the two counts are of different things — a depositary receipt against the ordinary shares behind it, or a count filed in thousands — and the count the price belongs to is used
• forward EPS growth -1.1% is analyst consensus, not a filing: consensus 2027 EPS 8.39 against trailing 8.58, over 2 year(s), from 6 analysts (taken 2026-10-11)
• PEG not measured: earnings are expected to grow -1.1%, and the ratio inverts at or below zero — a company whose profit is expected to fall faster would otherwise score better for it
• durability rests on 3 of 4 inputs; not tagged: gross margin stability